Dry Eye Disease (DED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : April 21, 2026
- Updated On : September 5, 2026
- Pages : 154
Dry Eye Disease Market Outlook and Forecast
Thelansis’s “Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dry Eye Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Dry Eye Disease Overview
Dry eye disease is a multifactorial ocular-surface disorder characterized by loss of tear-film homeostasis, with tear instability and hyperosmolarity, ocular-surface inflammation and damage, and neurosensory abnormalities contributing to symptoms and disease progression. Meibomian gland dysfunction is a major driver of evaporative disease, while aqueous deficiency and mixed phenotypes are also common. Artificial tears remain an important first-line option, but the therapeutic landscape has expanded substantially beyond lubrication. Mechanism-specific treatments now include lifitegrast and cyclosporine for inflammatory disease, perfluorohexyloctane for excessive tear evaporation, and nasal varenicline to stimulate natural tear production. Acoltremon, a TRPM8 agonist, further broadened the U.S. pharmacologic landscape in 2025 by introducing a sensory-pathway approach. The next development wave is increasingly focused on phenotype-specific biology, including kinase inhibition, neuromodulation, glandular restoration, and other approaches designed to improve tear-film stability and ocular-surface homeostasis. OT202, a dual SYK/VEGFR-2 inhibitor, demonstrated Phase 2 activity and entered Phase 3 development in 2026, while neuromodulation continues to gain clinical interest as a means of restoring endogenous tearing. For stakeholders, dry eye represents a large and increasingly segmented therapeutic market where future value will depend on matching mechanisms to specific disease phenotypes and delivering durable control of symptoms and ocular-surface damage.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Dry Eye Disease Market Outlook and Forecast
Thelansis’s “Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dry Eye Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Dry Eye Disease Overview
Dry eye disease is a multifactorial ocular-surface disorder characterized by loss of tear-film homeostasis, with tear instability and hyperosmolarity, ocular-surface inflammation and damage, and neurosensory abnormalities contributing to symptoms and disease progression. Meibomian gland dysfunction is a major driver of evaporative disease, while aqueous deficiency and mixed phenotypes are also common. Artificial tears remain an important first-line option, but the therapeutic landscape has expanded substantially beyond lubrication. Mechanism-specific treatments now include lifitegrast and cyclosporine for inflammatory disease, perfluorohexyloctane for excessive tear evaporation, and nasal varenicline to stimulate natural tear production. Acoltremon, a TRPM8 agonist, further broadened the U.S. pharmacologic landscape in 2025 by introducing a sensory-pathway approach. The next development wave is increasingly focused on phenotype-specific biology, including kinase inhibition, neuromodulation, glandular restoration, and other approaches designed to improve tear-film stability and ocular-surface homeostasis. OT202, a dual SYK/VEGFR-2 inhibitor, demonstrated Phase 2 activity and entered Phase 3 development in 2026, while neuromodulation continues to gain clinical interest as a means of restoring endogenous tearing. For stakeholders, dry eye represents a large and increasingly segmented therapeutic market where future value will depend on matching mechanisms to specific disease phenotypes and delivering durable control of symptoms and ocular-surface damage.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)